静脉接触胰腺腺癌新辅助化疗后切除与直接手术的比较:手术与生存结局分析
该回顾性研究比较了2006至2020年间169例接受胰十二指肠切除联合静脉切除的胰腺腺癌患者,其中55例术前行新辅助化疗、114例直接手术。新辅助化疗组病理学指标更优(肿瘤更小、R0率更高、淋巴结受累更少、病理性静脉侵犯率更低),且新辅助治疗与术中输血是总生存的独立预后因素。
核心结论
- 新辅助化疗改善了静脉切除胰十二指肠切除术治疗胰腺腺癌的病理学和生存结局,围术期输血的剂量依赖性效应值得进一步研究。
主要发现
- 两组手术时间、并发症发生率和死亡率无差异。
- 中位总生存为27.96个月,1年、3年、5年和10年总生存率分别为82%、39%、22%和11%。
临床怎么用
- 对于静脉接触的胰腺腺癌,新辅助化疗后行胰十二指肠切除联合静脉切除可能改善病理学结局和生存。
- 围术期输血与总生存呈剂量依赖性负相关,其效应需进一步研究。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant treatment before resection for pancreatic adenocarcinoma having contact with the splenomesentericoportal venous axis could improve the results of extended pancreatectomies. We compared the outcomes of upfront (UR) and resection after neoadjuvant chemotherapy (NAC) for pancreatic adenocarcinoma. METHODS: We retrospectively reviewed clinical data of patients who underwent pancreaticoduodenectomy with venous resection for pancreatic adenocarcinoma between January 1, 2006, and December 31, 2020. Operative, pathologic, and survival outcomes were compared between upfront and resection after neoadjuvant chemotherapy. RESULTS: Of the 169 patients, 55 patients underwent preoperative chemotherapy and 114 underwent upfront. No differences were found in operative time, morbidity, and mortality between the 2 groups. At pathologic examination, patients who underwent resection after neoadjuvant chemotherapy had a significantly smaller tumor size, higher rate of R0 resection, less lymph node involvement, and a lower rate of pathologic venous invasion (P < .05). The median overall survival was 27.96 months, and the overall survival rates at 1, 3, 5, and 10 years were 82%, 39%, 22%, and 11%, respectively. Multivariate Cox analysis found neoadjuvant treatment (hazard ratio: 0.60; 95% confidence interval: 0.38-0.97; P = .03), and intraoperative transfusion (hazard ratio: 2.25; 95% confidence interval: 1.47-3.46; P = .0002) as independent prognostic factors for overall survival. A dose-dependent effect of perioperative transfusion on overall survival was found (no transfusion, = 2 red blood cells, >2 red blood cells; median overall survival 41.1 months vs 27.01 months vs 19.4 months; P = .0003). CONCLUSION: Neoadjuvant chemotherapy improves the pathologic and survival outcomes of pancreaticoduodenectomy with venous resection for pancreatic adenocarcinomas. The dose-dependent effect of perioperative transfusion on overall survival warrants further investigation.
引用
- Addeo P, Cusumano C, Dufour P, et al. Upfront versus resection after neoadjuvant chemotherapy for pancreatic adenocarcinomas with venous contact: comparative analysis of operative and survival outcomes. Surgery. 2022. PMID: 35232605. doi:10.1016/j.surg.2022.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。